9939 — Kintor Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- HK$416.17m
- HK$311.76m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 34.2 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0 | 0 | 34.2 | 0 | -43.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 229 | 505 | 874 | 945 | 1,059 |
Operating Profit | -229 | -505 | -840 | -945 | -1,059 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -233 | -508 | -842 | -953 | -1,069 |
Provision for Income Taxes | |||||
Net Income After Taxes | -233 | -508 | -842 | -954 | -1,061 |
Net Income Before Extraordinary Items | |||||
Net Income | -233 | -508 | -842 | -954 | -1,061 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -233 | -508 | -842 | -954 | -1,061 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.794 | -1.6 | -2.36 | -2.37 | -2.27 |